VCAM-1 Protein & Antibody (CD106 Protein)

Vascular Cell Adhesion Molecule 1 (Cluster of Differentiation 106)

VCAM-1 / CD106 Products

VCAM-1 / CD106 Protein, Recombinant

Molecule	Species	Description	Cat. No
VCAM-1/CD106	Human	VCAM-1/CD106/Fc Protein, Recombinant	10113-H02H
VCAM-1/CD106	Human	VCAM-1/CD106 Protein, Recombinant	10113-H07H
VCAM-1/CD106	Human	VCAM-1/CD106 Protein, Recombinant	10113-H08H
VCAM-1/CD106	Mouse	VCAM-1/CD106 Protein, Recombinant	50163-M03H
VCAM-1/CD106	Mouse	VCAM-1/CD106 Protein, Recombinant	50163-M08H

  10113-H02H:  When cells are added to VCAM1 coated plates (10 µg/mL, 100 µg/well) approximately 90 %-100 % will adhere specifically. Measured by the ability of the immobilized protein to support the adhesion of U937 human histiocytic lymphoma cells.

  10113-H07H:  When cells are added to VCAM1 coated plates (10 µg/mL, 100 µg/well) approximately 85 %-95 % will adhere specifically. Measured by the ability of the immobilized protein to support the adhesion of U937 human histiocytic lymphoma cells.

  10113-H08H:  When 5 x 10⁴ cells / well are added to human VCAM1 coated plates (10 µg/mL with 100 µL/well), >70 % cells will adhere after 1 hour incubation at 37℃. Measured by the ability of the immobilized protein to support the adhesion of U937 human histiocytic lymphoma cells.

  50163-M03H:  When cells are added to VCAM1 coated plates (10 µg/mL, 100 µg/well) approximately 90 %-100 % will adhere specifically. Measured by the ability of the immobilized protein to support the adhesion of U937 human histiocytic lymphoma cells.

  50163-M08H: When 5 x 10⁴ cells / well are added to mouse VCAM1 coated plates (10 µg/mL with 100 µL/well) , approximately 70%-80% cells will adhere after 1 hour incubation at RT. Measured by the ability of the immobilized protein to support the adhesion of U937 human histiocytic lymphoma cells.

VCAM-1 / CD106 Antibody

Molecule	Application	Description	Cat. No
Mouse VCAM-1/CD106	WB, ELISA	VCAM-1 / CD106 Antibody	50163-RP01
Mouse VCAM-1/CD106	WB, ELISA	VCAM-1 / CD106 Antibody (Antigen Affinity Purified)	50163-RP02

VCAM-1 / CD106 cDNA Clone

Molecule	Species	Description	Cat. No
VCAM-1/CD106	Human	Homo sapiens VCAM-1/CD106 transcript variant 1 cDNA Clone(NM_001078.2)	HG10113-M
VCAM-1/CD106	Mosue	Mus musculus VCAM-1/CD106 cDNA Clone	MG50163-M
VCAM-1/CD106	Rat	VCAM1 cDNA Clone / ORF Clone	RG80233-G

VCAM-1 / CD106 Related Areas

Stem Cell>>Mesenchymal Stem Cell (MSC)>>Mesenchymal Stem Cell Marker>>VCAM-1/CD106

Stem Cell>>Hematopoietic Stem Cell (HSC)>>Hemangioblast>>Endothelial Cell Marker>>VCAM-1/CD106

Cancer>>Angiogenesis>>Adhesion Molecules in Angiogenesis>>VCAM-1/CD106

Immunology>>Adaptive Immunity>>T Cell>>T Cell Migration/Adhesion>>VCAM-1/CD106

Immunology>>Adhesion Molecule>>Cell Adhesion Molecule (IgSF CAM) >>VCAM-1/CD106

Immunology>>Cluster of Differentiation>>Monocyte/Macrophage CD Antigen>>Other>>VCAM-1/CD106

Immunology>>Cluster of Differentiation>>T Cell CD Antigen>>T Cell Migration/Adhesion>>VCAM-1/CD106

VCAM-1 / CD106 Alternative Names

VCAM-1, CD106, VCAM1, DKFZp779G2333, INCAM-100, MGC99561 [Homo sapiens]

VCAM-1, CD106, VCAM1 [Mus musculus]

VCAM-1 / CD106 Background

Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.

VCAM-1 / CD106 Related Studies

1. Cook-Mills JM. (2002) VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. Mol Immunol. 39(9): 499-508.
2. Preiss DJ, et al. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract. 61(4): 697-701.>